There Are Plenty of Eli Lilly Bulls: Here’s What They Aren’t Telling You
Eli Lilly's bulls are pointing at a 47% revenue surge and a pipeline loaded with blockbuster candidates, but there are a few uncomfortable details quietly buried in the earnings report that change how the story reads.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
At $1,137.76, Eli Lilly (NYSE:LLY | LLY Price Prediction) is a Hold. The bull chorus is loud, the fundamentals are real, and the stock is still a laggard against the market this year, which is exactly why the counterarguments deserve airtime before anyone chases it.
Lilly is the incretin franchise. Mounjaro and Zepbound combined for nearly $14.87 billion in Q2 alone, anchoring a portfolio that also spans oncology, immunology, and neuroscience. A $994.9 billion market cap and a rapidly expanding late-stage pipeline have made it the default long in large-cap pharma. The question is what price that story is worth.
Why the Bulls Keep Adding
Q2 revenue hit $22.97 billion, up 47.67% year over year, and EPS of $8.38 beat consensus by 27.27%, extending a four-quarter beat streak. Management raised full-year revenue guidance to $85.0 billion to $87.0 billion.
The pipeline reads like a bull’s wish list. Retatrutide showed “profound levels of weight loss” across three Phase 3 trials, with a BLA submission planned for Q1 2027. VERVE-102 cut PCSK9 by up to 88% and LDL-C by up to 62% in a single dose. On a forward basis, shares trade at roughly 24 times next year’s earnings, which the bull case argues is cheap for a company compounding revenue near 50%.
What the Bulls Are Not Telling You
Almost all the growth is volume, not price. Volume rose 60% while realized prices fell 13%, and U.S. prices declined roughly 9% excluding rebate adjustments. Management itself flagged that medical-exception pricing is “maybe a short-term thing” and that net price will “go down for sure” as CVS access opens.
Earnings quality is also softer than the headlines suggest. Acquired IPR&D charges hit $2.78 billion in Q2, part of a spree that added Orna, Ajax, Centessa, Kelonia, and now AtaiBeckley, whose sale process drew an investor investigation. Non-GAAP EPS guidance was narrowed to $35.50 to $36.50 from $35.50 to $37.00 despite the revenue raise. Novo is scaling oral obesity launches abroad, and generic semaglutide is already loose in India and Brazil.
Why Waiting Beats Chasing
Lilly is expensive, concentrated, and facing a pricing reset that has not yet shown up in the numbers. A trailing P/E of 37 demands that retatrutide clears the BLA pathway cleanly, that Foundeo scales globally in 2027, and that net pricing holds. Any one of those slipping resets the multiple.
History says post-earnings reactions can bite even after big beats. Q2 2025 beat by 12.89% and dropped 14.14% on the day. The next quarterly report, with harder comps and no rebate tailwind, is the fair place to make a bigger commitment.
What the Numbers Say About the Setup
Lilly currently trades at $1,137.76 against a mean analyst target of $1,318.66, implying meaningful upside. Those targets are not guarantees, only a snapshot of sell-side sentiment. Of 30 analysts, 6 rate it Strong Buy, 18 Buy, 4 Hold, 1 Sell, and 1 Strong Sell.
Valuation sits at 37 times trailing earnings and about 24 times forward, with a PEG of 1.10. The stock is up 6.38% year to date, trailing the S&P 500’s 11.57% gain, though it still leads over one year at 51.57% versus 15.73% for SPY.
Why Hold Is the Right Call at $1,137.76
At $1,137.76, Eli Lilly is a Hold.
The Buy trigger is clean visibility on net pricing and a BLA acceptance for retatrutide on the biologic pathway. If Q3 shows U.S. price stabilizing without rebate one-offs and the FDA aligns on the filing route management wants, the multiple is defensible and the stock can grow into it.
The Sell trigger is different. If net price steps down further as medical exceptions fade, if Novo’s oral products take share in Europe, or if the acquisition spree keeps pressuring reported EPS through more IPR&D charges, forward estimates come down and a 24 times multiple stops looking generous.
The cost of patience is missing another leg higher if retatrutide filing news breaks cleanly. The cost of acting now is buying a $1 trillion pharma into a pricing reset the company has already telegraphed. Waiting for the Q3 report to confirm which way the pricing curve bends is worth more than the implied upside currently on offer.
Lilly is a great business at a price that already assumes it stays great, which is why the right move is to let the next quarter do the arguing.
Contact [email protected] for any questions or corrections.
Alex Sirois is a financial writer with experience spanning both retail and institutional investing. He has written for InvestorPlace and held roles at BNY Mellon and Bernstein, giving him a perspective that bridges Main Street portfolios and Wall Street analysis.
Alex holds an MBA from George Washington University and has built his career across multiple industries, including e-commerce, education, and translation — a breadth of experience that informs how he breaks down complex financial topics for everyday investors. His writing is conversational, actionable, and grounded in long-term, buy-and-hold investing principles.
At 247 Wall St., Alex focuses on delivering analysis that is both accessible and useful, with a clear emphasis on helping readers make more informed decisions with their money.
